Are you Dr. Swan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
104 Abingdon Pl
Abingdon, VA 24211Phone+1 276-676-1860Fax+1 276-628-2917
Summary
- Dr. Forrest Swan Jr., MD is an oncologist in Abingdon, Virginia. He is currently licensed to practice medicine in Virginia, West Virginia, and Colorado. He is affiliated with Charleston Area Medical Center.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
- Loyola University Medical CenterResidency, Internal Medicine, 1978 - 1981
- University of Illinois College of MedicineClass of 1978
Certifications & Licensure
- FL State Medical License 1982 - 2026
- HI State Medical License 2018 - 2026
- TN State Medical License 1996 - 2026
- VA State Medical License 1996 - 2026
- WV State Medical License 2021 - 2025
- CO State Medical License 2019 - 2023
- WI State Medical License 1980 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- 218 citationsFludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.Peter McLaughlin, Fredrick B. Hagemeister, Jorge E. Romaguera, Andreas H. Sarris, Odeal Pate
Journal of Clinical Oncology. 1996-04-01 - 86 citationsPhase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.Peter McLaughlin, Fredrick B. Hagemeister, F. Swan, Fernando Cabanillas, Odeal Pate
Journal of Clinical Oncology. 1994-03-01 - 177 citationsPhase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.John R. Redman, Fernando Cabanillas, W. S. Velasquez, Peter McLaughlin, Fredrick B. Hagemeister
Journal of Clinical Oncology. 1992-05-01